| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,391 | 0,423 | 17.11. | |
| 0,402 | 0,410 | 17.11. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.10. | Valerio Therapeutics Completes Acquisition of Etherna Immunotherapies, Building an Integrated Targeted RNA Platform to Accelerate Progress Toward the Clinic | 725 | Business Wire | Shareholder approval and settlement and delivery of the capital increases related to the Acquisition
The Acquisition marks a major milestone in Valerio's strategy to build a leading integrated... ► Artikel lesen | |
| 07.10. | Valerio Therapeutics H1 Net Loss Widens Despite Higher Revenue; Shares Down | 4 | RTTNews | ||
| 07.10. | Valerio Therapeutics Provides an Update on Its Business and Presents Its Financial Results for the First Half of 2026 | 664 | Business Wire | Operational launch of InVimmune, a subsidiary dedicated to differentiated approaches to in vivo cell therapy, with a first indication announced in oncology.
Appointment of Gilles Besin... ► Artikel lesen | |
| 25.08. | Valerio Therapeutics To Acquire Etherna For €30 Million And Raise €40.25 Million PIPE To Build Targeted RNA Platform | 3 | pulse2.com | ||
| 24.08. | Valerio Therapeutics übernimmt Etherna für 30 Millionen Euro | 4 | Investing.com Deutsch | ||
| 24.08. | Valerio Therapeutics to acquire Etherna for €30 million | 4 | Investing.com | ||
| 24.08. | Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors | 741 | Business Wire | Definitive share purchase agreement signed for the acquisition of 100% of Etherna Immunotherapies NV ("Etherna"), and the related contribution agreement, based on an enterprise value of €30 million... ► Artikel lesen | |
| VALERIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 17.08. | Valerio Therapeutics and Etherna Immunotherapies Progress Towards Finalisation of Transaction Documentation Regarding the Contemplated Acquisition | 584 | Business Wire | Regulatory News:
Valerio Therapeutics (FR0010095596 ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), provides an update... ► Artikel lesen | |
| 16.07. | Valerio Therapeutics Announces Development Collaboration with Abivax and Provides Pipeline Update | 1.203 | Business Wire | Valerio and Abivax enter into a binding term-sheet for an exclusive global research and development collaboration Under the terms of the agreement Valerio will receive an upfront payment... ► Artikel lesen | |
| 01.07. | Valerio Therapeutics Announces Binding Offer for the Proposed Acquisition of Etherna Immunotherapies, Creating a Global Leader in Targeted RNA Medicines | 1.745 | Business Wire | The proposed acquisition represents a major step in Valerio's strategy to become a leading developer of next-generation targeted RNA medicines targeting cells beyond the liver, addressing diseases... ► Artikel lesen | |
| 16.06. | Valerio Therapeutics Appoints Gilles Besin as Chief Executive Officer and Announces Results of its Annual General Meeting | 1.061 | Business Wire | Seasoned biotech leader with deep expertise in RNA medicines, targeted delivery, and in vivo cell therapy joins to drive Valerio's next phase of innovation in precision targeted therapeutics
... ► Artikel lesen | |
| 18.05. | Valerio Therapeutics Announces Binding Term-Sheet for Collaboration and Exclusive License With Seed-Stage Biotech Company | 656 | Business Wire | Binding term-sheet for a potential aggregate amount of up to USD 200 million and tiered royalties
Regulatory News:
Valerio Therapeutics (FR0010095596 ALVIO), a biotechnology company specializing... ► Artikel lesen | |
| 04.05. | Valerio Therapeutics Announces the Launch of InVimmune, a New Company Dedicated to Developing Differentiated in Vivo Cell Therapy Approaches | 583 | Business Wire | Regulatory News:
Valerio Therapeutics (FR0010095596 ALVIO), a biotechnology company specializing in the development of technology platforms dedicated to the targeted delivery of innovative therapies... ► Artikel lesen | |
| 29.04. | Valerio Therapeutics Publishes Its 2025 Annual Results and Annual Financial Report, and Confirms the Strategic Transformation of Its Operating Model | 1.000 | Business Wire | Revenue: €2.6 million for the 2025 financial year, compared with €1.8 million in 2024 Operating expenses: €4.8 million, compared with €18.3 million in 2024 Creation of InVimmune... ► Artikel lesen | |
| 17.12.25 | Valerio Therapeutics Announces the Appointment of Professor Eric Vivier as Observer to Its Board of Directors | 739 | Business Wire | Regulatory News:
Valerio Therapeutics ("Valerio Therapeutics" or the "Company") (Euronext Growth Paris: ALVIO) announces the appointment of Professor Eric Vivier as an Observer to its Board of... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,15 | 0,00 % | BioNTech-Aktie: Totes Kapital? | Die Aktie von BioNTech bleibt trotz des rückläufigen Impfstoffgeschäfts ein spannender Titel am Aktienmarkt. Anleger richten ihren Blick zunehmend auf die milliardenschwere Forschungspipeline im Bereich... ► Artikel lesen | |
| EVOTEC | 2,750 | -6,34 % | Evotec-Aktie: Gewinn- und Umsatzrekord? | Die Aktie des Hamburger Wirkstoffforschers Evotec bleibt ein spannender, aber risikoreicher Titel am deutschen Aktienmarkt. Nach schwierigen Monaten sorgen erste operative Fortschritte, neue Partnerschaften... ► Artikel lesen | |
| BB BIOTECH | 57,00 | 0,00 % | Christian Koch, Leiter BB Biotech Team bei Bellevue Asset Management, im Interview | von Robert Jakob Moneycab.com: Herr Koch, acht bestehende Beteiligungen verkauft, zwölf neue Positionen aufgebaut, das sieht nach einer grösseren Rochade aus? Die Veränderungen spiegeln unser aktives... ► Artikel lesen | |
| MEDIGENE | 0,003 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| QIAGEN | 45,200 | -0,24 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| MODERNA | 188,04 | 0,00 % | Ihre wichtigsten Termine: Heute im Blickpunkt: Moderna, DocMorris, Applied Materials, Siemens und Cisco | © Foto: Bodo Schackow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: DE0008404005... ► Artikel lesen | |
| AMGEN | 415,95 | -0,04 % | Amgen Announces Positive Phase 3 Results For Dazodalibep In Sjögren's Disease | Only Global Phase 3 Trial to Show Clinically Meaningful Improvements in Systemic Disease Activity and Patient-Reported Symptoms of Sjögren's Disease THOUSAND OAKS, Calif., Nov. 11, 2026 /PRNewswire/... ► Artikel lesen | |
| VALNEVA | 2,559 | -0,85 % | Valneva: Starke Studien, aber der Chart bleibt wacklig - jetzt zählt die nächste Marke | ||
| EPIGENOMICS | 0,870 | 0,00 % | PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
Epigenomics AG: Veröffentlichung nach -- 40 Abs. 1 WpHG
Heidelberg (pta000/26.10.2026/15:00... ► Artikel lesen | |
| NOVAVAX | 7,200 | -0,41 % | Novavax hebt Prognose an: Worauf es jetzt ankommt | ||
| BIOGEN | 226,05 | -0,83 % | Biogen Inc.: Biogen's Diranersen Demonstrates Increasing Clinical Benefit at Two Years in Early Alzheimer's Disease | Diranersen slowed clinical decline by 38% on CDR-SB at two years (Week 96) with the 60 mg twice-yearly regimen, corresponding to a 1.09-point treatment differenceGreater slowing of clinical decline... ► Artikel lesen | |
| BIOFRONTERA | 2,840 | -3,07 % | Biofrontera AG: Was der Umsatzsprung nicht verrät | ||
| HEIDELBERG PHARMA | 2,040 | 0,00 % | Formycon, Heidelberg Pharma oder Medios: Welche Biotech-Aktie ist jetzt die stärkste? | ||
| ILLUMINA | 183,98 | -0,07 % | Illumina auf der Jefferies Global Healthcare Conference: Wachstum und Margen legen zu | ||
| CRISPR THERAPEUTICS | 36,550 | +0,23 % | 99 Millionen Dollar mit neuer Gentherapie: Vertex und CRISPR Therapeutics legen zu - Mesoblast wächst um 44 Prozent |